Literature DB >> 20845529

Words of wisdom. Re: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Scher HI, Beer TM, Higano CS, et al. Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium.

Kurt Miller1.   

Abstract

Entities:  

Year:  2010        PMID： 20845529     DOI： 10.1016/j.eururo.2010.06.018

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  3 in total

Review 1.  Contemporary role of androgen deprivation therapy for prostate cancer.

Authors:  Vincenzo Pagliarulo; Sergio Bracarda; Mario A Eisenberger; Nicolas Mottet; Fritz H Schröder; Cora N Sternberg; Urs E Studer
Journal:  Eur Urol       Date:  2011-08-19       Impact factor: 20.096

2.  Emerging novel therapies in the treatment of castrate-resistant prostate cancer.

Authors:  Alym Abdulla; Anil Kapoor
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

3.  Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays.

Authors:  Jin-Ping Pang; Chao Shen; Wen-Fang Zhou; Yun-Xia Wang; Lu-Hu Shan; Xin Chai; Ying Shao; Xue-Ping Hu; Feng Zhu; Dan-Yan Zhu; Li Xiao; Lei Xu; Xiao-Hong Xu; Dan Li; Ting-Jun Hou
Journal:  Acta Pharmacol Sin       Date:  2021-03-25       Impact factor: 7.169
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.